VP, Clinical Development

Ben joined Kymab in 2018 as VP of Clinical Development and Project Team Leader for its lead immunology asset, the anti-OX40L mAb, Amlitelimab SAR445229 (formerly KY1005). Ben led the development of the successful Phase 2a Atopic Dermatitis study.

Prior to joining Kymab Ben spent 16 years at Roche-Genentech, he worked in clinical development in a variety of roles including Global Development Leader for the anti-IL-6 mAb, tocilizumab (Acterma). and Global Head of Infectious Diseases with a focus on influenza, Hepatitis B and antimicrobial resistance and sat on a variety of cross therapeutic development review and leadership committees. Ben trained in medicine at Imperial College, London where he also completed a degree in Neuropharmacology and Neuroendocrinology. Ben is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians in the UK.